PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
26-Jan-2021 PromoCell GmbH receives EXCiPACT™ certification as manufacturer of pharmaceutical excipients to Good Manufacturing Practice (GMP) standards PromoCell GmbH
26-Jan-2021 SPT Labtech Announces a Co-Marketing Initiative with Thermo Fisher Scientific to Help Reduce the Cost of NGS Library Prep SPT Labtech
26-Jan-2021 Calibre Scientific Expands European Presence and Chromatography Offering With AIT France Acquisition Calibre Scientific
26-Jan-2021 New antimicrobial polymers as alternatives to antibiotics Emmy Noether Group
26-Jan-2021 ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment ViiV Healthcare
26-Jan-2021 BC Platforms, RIKEN and the Finnish Institute for Health and Welfare (THL) collaborate on artificial intelligence approach to identify people most at risk of from COVID-19 BC Platforms
26-Jan-2021 Investigating new treatment for schizophrenia as first Psychiatry Consortium funded project announced Earlham Institute
26-Jan-2021 European Commission Approves AbbVie’s RINVOQTM (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis AbbVie
26-Jan-2021 86% of Doctors Believe Mental Health Issues, Depression Will be the Biggest non-COVID-19 Issue as a Result of the Pandemic B3C newswire
26-Jan-2021 European Commission Approves AbbVie’s RINVOQTM (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis AbbVie
26-Jan-2021 BioMed X Institute Starts New Research Project in Drug Delivery in Collaboration with Janssen B3C newswire
26-Jan-2021 Release of results for the fourth quarter and full fiscal year 2019/20 (ending 30 September 2020) on 28 January 2021 Douglas GmbH
25-Jan-2021 MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer MorphoSys AG
25-Jan-2021 Siemens Healthineers AG: Disclosure pursuant to art. 5 para. 1 lit. b), para. 3 of the Regulation (EU) no. 596/2014 (MAR) and Art. 2 para. 3 of the Delegated Regulation (EU) No. 2016/1052 Siemens Healthineers AG
25-Jan-2021 Nass Valley Gateway Announces It Will Offer 30 New Products Including Flavored Hemp Smokables, CBD Beauty Line, and an Expanded Pet Menu Nass Valley Gateway Ltd.
25-Jan-2021 SPT Labtech announces acquisition of Apricot Designs SPT Labtech
25-Jan-2021 Albumedix submits Drug Master Files for its products in Japan Albumedix
25-Jan-2021 Solentim sets new standards in productivity with the launch of ICON™ and STUDIUS™; accelerating assurance rich workflows in the development of new biologics Sciad Newswire
25-Jan-2021 Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease RELIEF THERAPEUTICS Holdings AG
22-Jan-2021 Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform Accumulus Synergy